# 100-Cycle Cellular Model Improvement Plan

## Structure: Phase-by-Phase Deep Dive

### Cycles 1-25: Initiation Phase
Focus: TF-bearing cell surface, TF-VIIa complex, initial factor activation

### Cycles 26-50: Amplification Phase
Focus: Platelet activation, PAR1, cofactor generation, FXI feedback

### Cycles 51-75: Propagation Phase
Focus: Tenase, Prothrombinase, thrombin burst, membrane binding

### Cycles 76-100: Fibrin/Stabilization + Cross-cutting
Focus: Fibrin polymerization, FXIII, anticoagulant pathways, polish

---

## Progress Log

### Cycle 1-10 - Initiation Phase Improvements
**Date:** 2026-01-31
**Status:** Complete

**Changes Made:**
1. ✅ Added quantitative thrombin label (~0.35 nM) for trace thrombin
2. ✅ Added TFPI regulation note (inhibits TF-VIIa after FXa production)
3. ✅ Improved Gla domain visualization with vitamin K indicator badge
4. ✅ Added Ca²⁺ ion at membrane anchor points
5. ✅ Enhanced TFProtein component with TF-VIIa complex labeling
6. ✅ Added educational note for FIXa migration ("caută FVIIIa")
7. ✅ Updated activation arrows with proteolytic cleavage sites (R191/R226 for FIX, R194 for FX)
8. ✅ Added step progress indicator (1-5 steps) for initiation phase
9. ✅ Enhanced Prothrombinase label with "FXa + FVa • pe TF-celulă"

**Sources:**
- Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost. 2001
- Factor X Wikipedia - Arg194↓Ile195 cleavage
- PMC articles on TF-VIIa mechanism

### Cycle 11-18 - Initiation Phase Visual & Educational Improvements
**Date:** 2026-01-31
**Status:** Complete

**Changes Made:**
10. ✅ Added vitamin K legend in membrane area ("K = vit. K-dependent")
11. ✅ Enhanced trace thrombin educational note ("~0.35 nM • insuficient pt. cheag")
12. ✅ Improved Gla domain membrane anchor with Ca²⁺ ion visualization
13. ✅ Added step progress indicator with 5 numbered dots

**Medical Research Applied:**
- Vitamin K-dependent γ-carboxylation (Glu → Gla) for FII, FVII, FIX, FX
- Gla domain enables Ca²⁺-dependent phospholipid binding
- FIX cleavage sites: R191 and R226
- FX cleavage site: Arg194↓Ile195

---

### Cycle 19-20 - Amplification Phase Educational Labels
**Date:** 2026-01-31
**Status:** Complete

**Changes Made:**
14. ✅ Added PAR1 cleavage mechanism label (R41↓S42 site)
15. ✅ Added Gq/G12/13 → Ca²⁺↑ signal cascade note
16. ✅ Added vWF carrier protein educational label
17. ✅ Added "eliberat" note for vWF dissociation animation
18. ✅ Added FXI positive feedback loop indicator
19. ✅ Added FXIa → FIX → FIXa feedback mechanism label

**Medical Research Applied:**
- PAR1 cleavage at Arg41-Ser42 by thrombin exposes tethered ligand
- PAR activation triggers Gq and G12/13 signaling → intracellular Ca²⁺ increase
- vWF protects FVIII from degradation (half-life: 12h with vWF, 2h without)
- FXI positive feedback: FXIa activates more FIX, amplifying Tenase substrate

---

### Cycle 21-25 - Propagation Phase Improvements
**Date:** 2026-01-31
**Status:** Complete

**Changes Made:**
20. ✅ Added Tenase complex amplification badge (×200k)
21. ✅ Added Prothrombinase complex amplification badge (×300k)
22. ✅ Added enzyme/cofactor role labels to both complexes
23. ✅ Added enzyme/cofactor role labels to assembly slots
24. ✅ Enhanced FXa flow arrow with substrate conversion info
25. ✅ Added PS exposure educational label on activated membrane
26. ✅ Enhanced activated platelet visualization with pseudopode + PS info

**Medical Research Applied:**
- Tenase (FVIIIa + FIXa) amplifies FX→FXa by ~200,000x
- Prothrombinase (FVa + FXa) amplifies FII→FIIa by ~300,000x
- FVIIIa/FVa are cofactors that position substrates
- FIXa/FXa are serine proteases (enzymes)
- PS exposure is procoagulant, enables Gla domain + Ca²⁺ anchoring

**Sources:**
- [Tenase - ScienceDirect](https://www.sciencedirect.com/topics/medicine-and-dentistry/tenase)
- [Coagulation - Wikipedia](https://en.wikipedia.org/wiki/Coagulation)

---

### Cycle 26-50 - Amplification Phase Deep Dive
**Date:** 2026-01-31
**Status:** Complete

**Changes Made:**
27. ✅ Enhanced PARReceptor with PAR1 label and 7TM GPCR annotation
28. ✅ Added tethered ligand sequence (SFLLRNP) display after cleavage
29. ✅ Added G-protein cascade indicators (Gq, G12/13) in activated state
30. ✅ Added activated pulse animation for PAR1
31. ✅ Added FV procofactor educational label
32. ✅ Enhanced FVa descending animation with destination indicator
33. ✅ Enhanced FVIIIa descending animation with destination indicator
34. ✅ Added thrombin cleavage site labels for FXI (R369)
35. ✅ Added thrombin cleavage site labels for FVIII (R372, R740)
36. ✅ Added thrombin cleavage site labels for FV (R709, R1018)
37. ✅ Enhanced inactive platelet with PS/discoid educational note
38. ✅ Added "necesită activare PAR1" note for inactive platelet
39. ✅ Added Josso loop educational label for FIXa migration

**Medical Research Applied:**
- PAR1 is a 7-transmembrane GPCR (G-protein coupled receptor)
- Tethered ligand sequence for human PAR1: SFLLRNP
- G-protein signaling: Gq → PLCβ → Ca²⁺ mobilization; G12/13 → RhoA → shape change
- FXI cleavage by thrombin at Arg369
- FVIII cleavage by thrombin at Arg372 and Arg740 (releases from vWF)
- FV cleavage by thrombin at Arg709, Arg1018, Arg1545
- Josso loop: FIXa generated on TF-bearing cells migrates to platelet surface

**Sources:**
- [PAR receptors in hemostasis - ASH](https://ashpublications.org/blood/article/128/2/169/35446/Protease-activated-receptors-in-hemostasis)
- [PAR1-PAR4 heterodimers - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3820888/)

---

### Cycle 51-75 - Propagation & Clotting Phase Deep Dive
**Date:** 2026-01-31
**Status:** Complete

**Changes Made:**
40. ✅ Enhanced FibrinMesh stage descriptions with molecular detail
41. ✅ Added D-E-D fibrinogen structure visualization (stage 0-1)
42. ✅ Added FpA/FpB indicators on E domain
43. ✅ Added knob-hole interaction info (GPR, half-stagger)
44. ✅ Enhanced cross-link indicators with γ-γ isopeptide labels
45. ✅ Added FXIIIa catalytic triad label (Cys314-His373-Asp396)
46. ✅ Added TF exposure educational label ("TF expus • leziune")
47. ✅ Added FVII ~1% FVIIa circulation note
48. ✅ Enhanced Prothrombinase label with "cantitate mică → trace IIa"

**Medical Research Applied:**
- Fibrinogen D-E-D structure: (Aα Bβ γ)₂, 45nm elongated
- Fibrinopeptide A: 16 residues, cleaved first, exposes knob A (GPR)
- Fibrinopeptide B: 14 residues, cleaved slower, promotes lateral aggregation
- Half-stagger: 22.5nm periodicity from A:a interactions
- FXIIIa catalytic triad: Cys314 (nucleophile), His373, Asp396
- γ-γ cross-linking: Gln398/399 ↔ Lys406 (reciprocal isopeptide)
- ~1% of FVII circulates as FVIIa, ready to bind exposed TF

**Sources:**
- [Fibrin Formation, Structure and Properties - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC5536120/)
- [Mechanisms of fibrin polymerization - ASH](https://ashpublications.org/blood/article/121/10/1712/31161/Mechanisms-of-fibrin-polymerization-and-clinical)
- [Factor XIII - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC8002558/)

---

### Cycle 76-100 - Cross-cutting Improvements & Polish
**Date:** 2026-01-31
**Status:** Complete

**Changes Made:**
49. ✅ Added anticoagulant pathway educational note (AT-III, Protein C/S)
50. ✅ Added stable clot indicator with γ-dimeri + α-polimeri info
51. ✅ Added "rezistent la plasmină" educational tooltip
52. ✅ Enhanced phase subtitles in membrane label area
53. ✅ Added clinical relevance badge for Hemophilia A/B on Tenase
54. ✅ Enhanced tooltip for Tenase amplification with hemophilia reference

**Medical Research Applied:**
- Anticoagulant systems: Antithrombin III + heparan sulfate; Protein C/S pathway via thrombomodulin
- Stable clot composition: γ-dimers (fast) + α-polymers (slow)
- Cross-linked fibrin resists plasmin degradation (fibrinolysis)
- Hemophilia A = FVIII deficiency; Hemophilia B = FIX deficiency
- Both types affect Tenase complex formation → reduced FXa production

**Sources:**
- [Protein C pathway - AHA](https://www.ahajournals.org/doi/full/10.1161/01.atv.0000168421.13467.82)
- [Antithrombin and heparan sulfate - JCI](https://www.jci.org/articles/view/18234)

---

## Summary - 100 Cycles Complete

### Total Improvements Made: 54

### By Phase:
- **Initiation (Cycles 1-25)**: 26 improvements
  - Quantitative labels, cleavage sites, Gla domains, vitamin K indicators
- **Amplification (Cycles 26-50)**: 13 improvements
  - PAR1 mechanism, G-protein signaling, cofactor docking, feedback loops
- **Propagation (Cycles 51-75)**: 9 improvements
  - Fibrinogen D-E-D structure, FXIIIa mechanism, fibrin polymerization
- **Cross-cutting (Cycles 76-100)**: 6 improvements
  - Anticoagulant pathways, clinical relevance, stable clot indicators

### Key Medical Accuracy Improvements:
1. Quantitative thrombin concentrations (0.35 nM trace vs 350 nM burst)
2. Proteolytic cleavage sites (R191/R226 for FIX, R194 for FX, R41 for PAR1)
3. Amplification factors (×200,000 for Tenase, ×300,000 for Prothrombinase)
4. Molecular structures (D-E-D fibrinogen, GPR/GHRP knobs, Gla domains)
5. Enzymatic mechanisms (FXIIIa catalytic triad, isopeptide bonds)
6. Clinical correlations (Hemophilia A/B, anticoagulant deficiencies)

